Literature DB >> 21547107

Erythrocytapheresis: Do Not Forget a Useful Therapy!

Heidrun Ullrich1, Roland Fischer, Regine Grosse, Uwe Kordes, Claudia Schubert, Bettina Altstadt, Georges Andreu.   

Abstract

SUMMARY: In patients with pathologically altered erythrocytes, red blood cell exchange is a very efficient therapeutic measure without important side effects. With increasing migration more patients with e.g. severe malaria or sickle cell anemia have to be treated. In minor or bidirectional ABO-mismatched stem cell transplantations after reduced intensity conditioning, hemolysis can be prevented by prophylactic erythrocytapheresis. Other rare indications for red blood cell exchange are advanced erythropoietic protoporphyria and babesiosis. Sickle cell anemia can be treated with hydroxyurea. Transfusions are administered when necessary, but this results in iron overload in the long term. An expensive but safe and very efficient treatment alternative is red blood cell exchange. In cases with stroke, acute chest syndrome and other severe complications, erythrocytapheresis reproducibly breaks the vicious circle of sickling and increasing oxygen deficiency. At the same time one can aim at an exact end hematocrit. In severe malaria, erythrocytapheresis both reduces parasite load to the designated extent and reconstitutes reduced oxygen transport capacity without serious adverse effects. Here we describe our experience of erythrocytapheresis in long-term prophylaxis of complications in sickle cell anemia and sickle cell thalassemia patients. The documentation of improved iron balance was carried out by liver susceptometry.

Entities:  

Year:  2008        PMID: 21547107      PMCID: PMC3083277          DOI: 10.1159/000112044

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  32 in total

1.  Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis.

Authors:  Mark S Riddle; Jeffrey L Jackson; John W Sanders; David L Blazes
Journal:  Clin Infect Dis       Date:  2002-04-03       Impact factor: 9.079

2.  Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis.

Authors:  Clinton Baldwin; Vikki G Nolan; Diego F Wyszynski; Qian-Li Ma; Paola Sebastiani; Stephen H Embury; Alice Bisbee; John Farrell; Lindsay Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

3.  Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway.

Authors:  Vikki G Nolan; Adeboye Adewoye; Clinton Baldwin; Ling Wang; Qianli Ma; Diego F Wyszynski; John J Farrell; Paola Sebastiani; Lindsay A Farrer; Martin H Steinberg
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

4.  Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.

Authors:  P Harmatz; E Butensky; K Quirolo; R Williams; L Ferrell; T Moyer; D Golden; L Neumayr; E Vichinsky
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

5.  Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.

Authors:  Robert J Adams; Donald Brambilla
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

6.  alpha-Klotho as a regulator of calcium homeostasis.

Authors:  Akihiro Imura; Yoshihito Tsuji; Miyahiko Murata; Ryota Maeda; Koji Kubota; Akiko Iwano; Chikashi Obuse; Kazuya Togashi; Makoto Tominaga; Naoko Kita; Ken-ichi Tomiyama; Junko Iijima; Yoko Nabeshima; Makio Fujioka; Ryo Asato; Shinzo Tanaka; Ken Kojima; Juichi Ito; Kazuhiko Nozaki; Nobuo Hashimoto; Tetsufumi Ito; Takeshi Nishio; Takashi Uchiyama; Toshihiko Fujimori; Yo-ichi Nabeshima
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

7.  Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.

Authors:  Nina Worel; Hildegard T Greinix; Volker Supper; Gerda Leitner; Margit Mitterbauer; Werner Rabitsch; Gottfried Fischer; Agathe Rosenmayr; Paul Höcker; Peter Kalhs
Journal:  Transfusion       Date:  2007-08       Impact factor: 3.157

8.  Automated red cell exchange procedures in patients with sickle cell disease.

Authors:  Ilknur Kozanoglu; Can Boga; Hakan Ozdogu; Nurzen Sezgin; Ebru Kizilkilic; Mahmut Kural
Journal:  Transfus Apher Sci       Date:  2007-06-20       Impact factor: 1.764

9.  Gene interactions and stroke risk in children with sickle cell anemia.

Authors:  Carolyn Hoppe; William Klitz; Suzanne Cheng; Ray Apple; Lori Steiner; Lara Robles; Tom Girard; Elliott Vichinsky; Lori Styles
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

10.  A network model to predict the risk of death in sickle cell disease.

Authors:  Paola Sebastiani; Vikki G Nolan; Clinton T Baldwin; Maria M Abad-Grau; Ling Wang; Adeboye H Adewoye; Lillian C McMahon; Lindsay A Farrer; James G Taylor; Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood       Date:  2007-06-28       Impact factor: 22.113

View more
  2 in total

1.  Therapeutic Apheresis - Many Ways to Go.

Authors:  Rainer Moog
Journal:  Transfus Med Hemother       Date:  2008-01-15       Impact factor: 3.747

2.  Successful Use of Adjunctive Red Blood Cell Exchange Therapy for Treatment of an Acute Hemolytic Reaction After ABO-Incompatible Red Blood Cell Transfusion.

Authors:  Sammy Moussly; Jacqueline Kropf; Nawid Sarwari; Jose Sarriera; Steve Carlan; Mario Madruga
Journal:  J Hematol (Brossard)       Date:  2019-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.